Targeting the NOX4/NLRP Inflammasome Axis Confers Protection by Isoliquiritigenin Against H₂O₂-Induced Synovial Inflammation.

Authors

Yu-Chun Chang, Wei-Wen Kuo, Yen-Pin Chen, Shih-Wen Kao, Dennis Jine-Yuan Hsieh, Tsung-Jung Ho, Chia-Hua Kuo, Chien-Yao Fu, Chih-Yang Huang, Shinn-Zong Lin

Published in

Chemico-biological interactions. Pages 112267. Jul 24, 2026. Epub Jul 24, 2026.

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation and progressive joint destruction. Fibroblast-like synoviocytes (FLS) play a central role in RA pathogenesis by promoting inflammatory signaling and extracellular matrix (ECM) degradation. Although isoliquiritigenin (ISL) exhibits anti-inflammatory and antioxidant activities, its direct molecular target in RA remains unclear. Therefore, this study aimed to identify the molecular target of ISL and elucidate its underlying mechanism. To address this, integrated bioinformatics analysis, target validation (CETSA, DARTS, and molecular docking), together with mechanistic studies in H₂O₂-treated synovial cells and CIA rats, were performed. Bioinformatics analysis identified NADPH oxidase 4 (NOX4) as one of the overlapping candidate targets of ISL for further investigation. Target engagement of NOX4 by ISL was supported by CETSA, DARTS, and molecular docking analyses. ISL suppressed NOX4-mediated reactive oxygen species (ROS) production, thereby inhibiting inflammasome activation, pro-inflammatory cytokine production, apoptosis, and ECM degradation.ISL improved cell survival and reduced apoptosis in H₂O₂-treated synovial c ells while preserving ECM integrity. These protective effects were further confirmed in CIA rats, where ISL alleviated arthritis severity, oxidative stress, and cartilage destruction. Collectively, these findings identify NOX4 as a critical upstream regulator linking oxidative stress to inflammasome activation and support pharmacological targeting of the NOX4-ROS-inflammasome axis by ISL as a promising therapeutic approach for RA.

PMID:
42498242
Bibliographic data and abstract were imported from PubMed on 25 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.